Methodological challenges in pragmatic trials in Alzheimer's disease and related dementias: Opportunities for improvement

被引:6
|
作者
Taljaard, Monica [1 ,2 ]
Li, Fan [3 ]
Qin, Bo [3 ]
Cui, Caroline [3 ]
Zhang, Leyi [3 ]
Nicholls, Stuart G. [1 ]
Carroll, Kelly [1 ]
Mitchell, Susan L. [4 ]
机构
[1] Ottawa Hosp Res Inst, Clin Epidemiol Program, Civ Campus,1053 Carling Ave,Civ Box 693, Ottawa, ON K1Y 4E9, Canada
[2] Univ Ottawa, Sch Epidemiol & Publ Hlth, Ottawa, ON, Canada
[3] Yale Univ, Yale Sch Publ Hlth, Dept Biostat, New Haven, CT USA
[4] Hebrew Senior Life Marcus Inst Aging Res, Boston, MA USA
基金
加拿大健康研究院; 美国国家卫生研究院;
关键词
Cluster randomized trials; longitudinal data analysis; multilevel modeling; missing data; intracluster correlation; pragmatic trials; Alzheimer's disease; dementia; COVARIATE-DEPENDENT MISSINGNESS; SAMPLE-SIZE DETERMINATION; CLINICAL-TRIALS; OUTCOMES; DESIGN; POWER;
D O I
10.1177/17407745211046672
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background and Aims We need more pragmatic trials of interventions to improve care and outcomes for people living with Alzheimer's disease and related dementias. However, these trials present unique methodological challenges in their design, analysis, and reporting-often, due to the presence of one or more sources of clustering. Failure to account for clustering in the design and analysis can lead to increased risks of Type I and Type II errors. We conducted a review to describe key methodological characteristics and obtain a "baseline assessment" of methodological quality of pragmatic trials in dementia research, with a view to developing new methods and practical guidance to support investigators and methodologists conducting pragmatic trials in this field. Methods We used a published search filter in MEDLINE to identify trials more likely to be pragmatic and identified a subset that focused on people living with Alzheimer's disease or other dementias or included them as a defined subgroup. Pairs of reviewers extracted descriptive information and key methodological quality indicators from each trial. Results We identified N = 62 eligible primary trial reports published across 36 different journals. There were 15 (24%) individually randomized, 38 (61%) cluster randomized, and 9 (15%) individually randomized group treatment designs; 54 (87%) trials used repeated measures on the same individual and/or cluster over time and 17 (27%) had a multivariate primary outcome (e.g. due to measuring an outcome on both the patient and their caregiver). Of the 38 cluster randomized trials, 16 (42%) did not report sample size calculations accounting for the intracluster correlation and 13 (34%) did not account for intracluster correlation in the analysis. Of the 9 individually randomized group treatment trials, 6 (67%) did not report sample size calculations accounting for intracluster correlation and 8 (89%) did not account for it in the analysis. Of the 54 trials with repeated measurements, 45 (83%) did not report sample size calculations accounting for repeated measurements and 19 (35%) did not utilize at least some of the repeated measures in the analysis. No trials accounted for the multivariate nature of their primary outcomes in sample size calculation; only one did so in the analysis. Conclusion There is a need and opportunity to improve the design, analysis, and reporting of pragmatic trials in dementia research. Investigators should pay attention to the potential presence of one or more sources of clustering. While methods for longitudinal and cluster randomized trials are well developed, accessible resources and new methods for dealing with multiple sources of clustering are required. Involvement of a statistician with expertise in longitudinal and clustered designs is recommended.
引用
收藏
页码:86 / 96
页数:11
相关论文
共 50 条
  • [21] Neuropsychiatric assessment of Alzheimer’s disease and related dementias
    J. L. Cummings
    S. McPherson
    Aging Clinical and Experimental Research, 2001, 13 : 240 - 246
  • [22] The Health Economics of Alzheimer's Disease and Related Dementias
    Rapp, Thomas
    Lin, Pei-Jung
    VALUE IN HEALTH, 2025, 28 (04) : 495 - 496
  • [23] microRNAs in Sporadic Alzheimer's Disease and Related Dementias
    Hebert, Sebastien S.
    Mandemakers, Wim
    Papadopoulou, Aikaterini S.
    DeStrooper, Bart
    MACRO-ROLES FOR MICRORNAS IN THE LIFE AND DEATH OF NEURONS, 2010, : 91 - +
  • [24] Methodological challenges in assessing the impact of comorbidities on costs in Alzheimer’s disease clinical trials
    Kristin Kahle-Wrobleski
    Howard Fillit
    Jonathan Kurlander
    Catherine Reed
    Mark Belger
    The European Journal of Health Economics, 2015, 16 : 995 - 1004
  • [25] Methodological challenges in assessing the impact of comorbidities on costs in Alzheimer's disease clinical trials
    Kahle-Wrobleski, Kristin
    Fillit, Howard
    Kurlander, Jonathan
    Reed, Catherine
    Belger, Mark
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2015, 16 (09): : 995 - 1004
  • [26] Analysis of eligibility criteria in Alzheimer's and related dementias clinical trials
    Mitchell, Alexandra K.
    Ehrenkranz, Rebecca
    Franzen, Sanne
    Han, Sae H.
    Shakur, Mujaahida
    McGowan, Melissa
    Massett, Holly A.
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [27] USE OF CMS DATA SOURCES IN THE STUDY OF ALZHEIMER'S DISEASE AND RELATED DEMENTIAS: ISSUES AND CHALLENGES
    Walsh, E.
    McCall, N.
    GERONTOLOGIST, 2008, 48 : 755 - 755
  • [28] Health equity considerations in pragmatic trials in Alzheimer's and dementia disease: Results from a methodological review
    Nicholls, Stuart G.
    Al-Jaishi, Ahmed A.
    Niznick, Harrison
    Carroll, Kelly
    Madani, Mohamad Tarek
    Peak, Katherine D.
    Madani, Leen
    Nevins, Pascale
    Adisso, Lionel
    Li, Fan
    Weijer, Charles
    Mitchell, Susan L.
    Welch, Vivian
    Quinones, Ana R.
    Taljaard, Monica
    ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING, 2023, 15 (01)
  • [29] Metformin as a Potential Prevention Strategy for Alzheimer's Disease and Alzheimer's Disease Related Dementias
    Tahmi, Mouna
    Benitez, Richard
    Luchsinger, Jose
    JOURNAL OF ALZHEIMERS DISEASE, 2024, 101 : S345 - S356
  • [30] The ABC of Alzheimer's disease: Cognitive changes and their management in Alzheimer's disease and related dementias
    Corey-Bloom, J
    INTERNATIONAL PSYCHOGERIATRICS, 2002, 14 : 51 - 75